Guardant Health opened lower at $182.48, compared with its previous close of $185.31. In the last trading session, the stock traded between $176.96 and $185.65. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Guardant Health is now worth
$ 151.94
giving a profit of
$ 51.94 (51.94%)
Note: Past profits do not guarantee future returns.
Rating from 20 Analysts
Today's Change
$-7.86 (-4.24%)
Day High
$185.65
Day Low
$176.96
Day Open
$182.48
Prev Close
$185.31
Volume
5,40,339
1W Return
8.82%
1M Return
-0.22%
3M Return
23.04%
6M Return
112.74%
1Y Return
145.54%
Market Cap ($ Mn)
23,813
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-35.98%
EPS (TTM)
$-0.90
1 Week
8.82%
1 Month
-0.22%
3 Months
23.04%
6 Months
112.74%
9 Months
60.62%
Guardant Health Shield test shows 99% adherence in rural clinics
Shield blood test showed 99% adherence in rural South Carolina clinics. Modeling study projected 12 CRC deaths averted per 1,000 people vs 6 for FIT. Blood-based testing increased colonoscopies to 679 vs 113 for FIT. Adherence rates far exceed the 28-71% average for standard CRC screening.
15 days agoGuardant Health sets Q3 2026 earnings release for November 5
Guardant Health will release Q3 2026 financial results on November 5, 2026. Conference call scheduled for 4:30 pm ET after market close. Webcast available via the company's investor relations website.
21 days agoGuardant Health secures European approval for Guardant360 CDx
Guardant360 CDx receives CE-marking in Europe for ETCAMAH treatment. Marks the 31st CDx approval for Guardant Health globally. Enables early detection of ESR1 mutations via blood draw. Follows prior approvals in the United States and Japan.
21 days agoGuardant Reveal detects melanoma recurrence 70 days before clinical signs
Guardant Reveal showed 81% sensitivity for distant recurrence and 100% post-treatment specificity. ctDNA detection preceded clinical recurrence by a median of 70.5 days. MRD detection linked to 12-fold increased risk of recurrence and >30-fold risk of death. Study analyzed 280 samples from 48 patients with resected stage II-III melanoma.
25 days agoGuardant Health Shield test covered by EviCore from Jan 1, 2027
Guardant Health Shield test covered by EviCore by Evernorth from Jan 1, 2027. Total covered lives for Shield rise to approximately 94 million in the US. Expansion follows earlier coverage wins with Carelon and UnitedHealth Group. Test targets average-risk adults aged 45+ per ACS guidelines.
1mo agoFDA approves Guardant Health test for AstraZeneca's camizestrant in breast cancer
FDA approved Guardant360 CDx as companion diagnostic for AstraZeneca's camizestrant. Targets HR-positive, HER2-negative advanced breast cancer patients with ESR1 mutations. Approval marks 29th companion diagnostic indication for Guardant Health globally. SERENA-6 trial showed 74% improvement in median progression-free survival.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $252.92 | +2.97% | $27,826.01M | 25.77 | |
| $677.56 | -2.18% | $18,952.71M | 35.27 |
An investment of $100 made 5 years ago in Guardant Health is now worth
$ 151.94
giving a profit of
$ 51.94 (51.94%)
Note: Past profits do not guarantee future returns.
